These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31466832)

  • 1. Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice.
    Yoshioka H; Ohishi R; Hirose Y; Torii-Goto A; Park SJ; Miura N; Yoshikawa M
    Obes Res Clin Pract; 2019; 13(5):505-510. PubMed ID: 31466832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diurnal Variation of Sitagliptin-Induced Pharmacological Effects in C57BL/6J Mice.
    Yoshioka H; Hirose Y; Ohishi R; Tominaga S; Torii-Goto A; Park SJ; Miura N; Yoshikawa M
    Biol Pharm Bull; 2019; 42(9):1562-1568. PubMed ID: 31474716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
    Yabiku K; Nakamoto K; Tsubakimoto M
    J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
    Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
    Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model.
    Yang M; Shi FH; Liu W; Zhang MC; Feng RL; Qian C; Liu W; Ma J
    Front Endocrinol (Lausanne); 2020; 11():635. PubMed ID: 33312157
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
    Sayed N; Abdalla O; Kilany O; Dessouki A; Yoshida T; Sasaki K; Shimoda M
    J Vet Med Sci; 2020 Apr; 82(4):467-474. PubMed ID: 32161237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
    Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
    Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load.
    Sato D; Nakamura T; Amarume J; Yano M; Nishina A; Feng Z; Kusunoki M
    J Pharmacol Sci; 2022 Jan; 148(1):86-92. PubMed ID: 34924134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
    Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
    BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.
    Kanno A; Asahara SI; Kawamura M; Furubayashi A; Tsuchiya S; Suzuki E; Takai T; Koyanagi-Kimura M; Matsuda T; Okada Y; Ogawa W; Kido Y
    J Diabetes Investig; 2019 May; 10(3):577-590. PubMed ID: 30290061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.